MAPK8 and malignant colon neoplasm: AS601245 [1,3-Benzothiazol-2-yl-(2-{[2-(3-pyridinyl)ethyl]amino}-4-pyrimidinyl) acetonitrile; JNK inhibitor V] has been selected as a potent and selective JNK inhibitor with anti-inflammatory properties [24], and has been used in the present work to assess its involvement with anti-carcinogenic effects displayed by rosiglitazone in colon cancer cells.